MX2015011445A - Compuestos y usos de estos para la modulacion de la hemoglobina. - Google Patents

Compuestos y usos de estos para la modulacion de la hemoglobina.

Info

Publication number
MX2015011445A
MX2015011445A MX2015011445A MX2015011445A MX2015011445A MX 2015011445 A MX2015011445 A MX 2015011445A MX 2015011445 A MX2015011445 A MX 2015011445A MX 2015011445 A MX2015011445 A MX 2015011445A MX 2015011445 A MX2015011445 A MX 2015011445A
Authority
MX
Mexico
Prior art keywords
hemoglobin
compounds
modulation
methods
disorders
Prior art date
Application number
MX2015011445A
Other languages
English (en)
Inventor
Li Zhe
Ii Stephen L Gwaltney
Qing Xu
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/815,735 external-priority patent/US8952171B2/en
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of MX2015011445A publication Critical patent/MX2015011445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

En la presente se proporcionan compuestos y composiciones farmacéuticas adecuados como moduladores de la hemoglobina, métodos e intermedios para su preparación, y métodos para su uso en el tratamiento de trastornos mediados por la hemoglobina y trastornos que se podrían beneficiar de la oxigenación celular y/o tisular.
MX2015011445A 2013-03-15 2014-03-10 Compuestos y usos de estos para la modulacion de la hemoglobina. MX2015011445A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/815,735 US8952171B2 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US201361905803P 2013-11-18 2013-11-18
PCT/US2014/022769 WO2014150268A1 (en) 2013-03-15 2014-03-10 Compounds and uses thereof for the modulation of hemoglobin

Publications (1)

Publication Number Publication Date
MX2015011445A true MX2015011445A (es) 2016-04-20

Family

ID=51580732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011445A MX2015011445A (es) 2013-03-15 2014-03-10 Compuestos y usos de estos para la modulacion de la hemoglobina.

Country Status (22)

Country Link
US (3) US20160083343A1 (es)
EP (1) EP2970196B1 (es)
JP (3) JP6426694B2 (es)
KR (1) KR102280614B1 (es)
CN (2) CN112500338A (es)
AP (1) AP2015008721A0 (es)
AU (3) AU2014237340C1 (es)
BR (1) BR112015021985B1 (es)
CA (1) CA2903220C (es)
CL (1) CL2015002501A1 (es)
EA (1) EA034922B1 (es)
ES (1) ES2852054T3 (es)
IL (1) IL241060B (es)
MX (1) MX2015011445A (es)
MY (1) MY191087A (es)
PE (1) PE20161035A1 (es)
SA (2) SA515361026B1 (es)
SG (2) SG10201802911RA (es)
TW (1) TWI695830B (es)
UY (1) UY35426A (es)
WO (1) WO2014150268A1 (es)
ZA (1) ZA201703791B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PL3738434T3 (pl) 2011-12-28 2024-03-04 Global Blood Therapeutics, Inc. Związki pośrednie do otrzymywania podstawionych związków benzaldehydowych i sposoby ich zastosowania do zwiększania natlenienia tkanek
WO2014150276A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) * 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG11201510135XA (en) 2014-02-07 2016-01-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2016043849A2 (en) * 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CN113316568A (zh) 2018-11-19 2021-08-27 全球血液疗法股份有限公司 能够调节血红蛋白的2-甲酰基-3-羟基苯基氧基甲基化合物
CR20210284A (es) 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina
WO2021202284A1 (en) 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (435)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258226C (es)
DE226590C (es)
DE276479C (es)
BE558821A (es) 1956-02-13 1900-01-01
BE787580A (fr) 1971-08-13 1973-02-14 Hoechst Ag Procede de preparation de derives du furanne
BE787576A (fr) 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
FI71929C (fi) 1979-06-29 1987-03-09 Wellcome Found Foerfarande foer framstaellning av terapeutiskt anvaendbara eterfoereningar samt vid deras framstaellning anvaendbara mellanprodukter.
IT1193786B (it) * 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
JPS5929667A (ja) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
DE3431004A1 (de) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPS63258463A (ja) * 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (ja) 1988-01-27 1997-09-03 サントリー株式会社 ピロリチジン化合物およびその用途
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (it) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
AU641769B2 (en) 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0487745A4 (en) 1990-06-19 1993-01-20 Meiji Seika Kabushiki Kaisha Pyridine derivative with angiotensin ii antagonism
NL9001752A (nl) 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
JPH05301872A (ja) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
WO1992013841A1 (de) 1991-02-08 1992-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
JPH0641118A (ja) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
EP0648209A1 (de) 1992-07-01 1995-04-19 Byk Gulden Lomberg Chemische Fabrik GmbH Kontrastmittel für die mr diagnostik
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
WO1994022857A1 (en) 1993-04-07 1994-10-13 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
DE4318550A1 (de) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5534529A (en) 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JPH0725882A (ja) 1993-07-07 1995-01-27 Res Dev Corp Of Japan アクロメリン酸ｂおよびｅを製造するための中間体と、その製造方法
DK0637586T3 (da) 1993-08-05 1999-12-06 Hoechst Marion Roussel Inc 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
EP0750631B1 (en) 1994-02-14 2000-04-05 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (de) 1994-11-25 1996-05-30 Hoechst Ag Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
GB9604311D0 (en) 1996-02-29 1996-05-01 Merck & Co Inc Inhibitors of farnesyl-protein transferase
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
JP3895404B2 (ja) 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
WO1997041120A1 (en) 1996-07-26 1997-11-06 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
AU4136197A (en) 1996-09-09 1998-03-26 Kyowa Hakko Kogyo Co. Ltd. Pyrrolocarbazole derivatives
US6204221B1 (en) 1996-11-12 2001-03-20 Syngenta Crop Protection, Inc. Herbicides
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
FR2761069A1 (fr) 1997-03-20 1998-09-25 Pf Medicament Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU9695198A (en) 1997-10-17 1999-05-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
WO1999031104A1 (en) 1997-12-12 1999-06-24 Euro-Celtique, S.A. Preparation of 3-substituted adenines and imidazo pyridines
KR20010041346A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 ａ2 억제제
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
BR9909277A (pt) 1998-03-31 2001-10-16 Acadia Pharm Inc Compostos com atividade em receptores muscarìnicos
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
YU41801A (sh) 1998-12-14 2003-12-31 F. Hofman - La Roche Ag. Derivati fenilglicina
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
EP1150957A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
CA2362401A1 (en) 1999-02-04 2000-08-10 Paul Fleming G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CA2368451A1 (en) * 1999-03-31 2000-10-05 Basf Aktiengesellschaft Pyridine-2,3-dicarboxylic acid diamides
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
CN1183113C (zh) 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 作为ppar受体配体的三芳基酸衍生物
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US6747028B1 (en) 1999-06-28 2004-06-08 Hanssen Pharmaceutica, N.V. Respiratory syncytial virus replication inhibitors
AU782114B2 (en) 1999-09-28 2005-07-07 Eisai R&D Management Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
SE9903759D0 (sv) 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
CA2390025A1 (en) 1999-11-05 2001-05-10 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2001057044A1 (fr) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Derives de pyrido-oxazine
FR2804431A1 (fr) 2000-02-02 2001-08-03 Adir Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
CA2403553A1 (en) 2000-03-17 2001-09-27 David Johnson Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
EP1303490B1 (en) 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US20020142995A1 (en) 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002012224A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
IL155702A0 (en) 2000-11-20 2003-11-23 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002051849A1 (fr) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs cdk4
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
US20040077654A1 (en) 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0100326D0 (sv) 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
SE0101324D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New process
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US20030073712A1 (en) 2001-07-23 2003-04-17 Bing Wang Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
JP2003075970A (ja) 2001-08-31 2003-03-12 Konica Corp ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法
KR100467313B1 (ko) 2001-11-22 2005-01-24 한국전자통신연구원 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002360763A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
DE60321775D1 (de) 2002-04-03 2008-08-07 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
WO2004014899A1 (en) * 2002-08-08 2004-02-19 Smithkline Beecham Corporation Thiophene compounds
MXPA05001590A (es) 2002-08-09 2005-05-23 Astrazeneca Ab Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
BR0313266A (pt) 2002-08-09 2005-06-21 Astrazeneca Ab Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7368578B2 (en) 2002-09-10 2008-05-06 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
GB0223712D0 (en) 2002-10-14 2002-11-20 Astrazeneca Ab Chemical intermediate
US7160910B2 (en) 2002-12-04 2007-01-09 Xechem International, Inc. Anti-sickling agents
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
WO2004056727A2 (en) 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
WO2004073675A1 (de) 2003-02-24 2004-09-02 Randolph Riemschneider Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JPWO2004089410A1 (ja) 2003-04-03 2006-07-06 協和醗酵工業株式会社 神経因性疼痛の予防及び／または治療剤
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
US7396935B2 (en) 2003-05-01 2008-07-08 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
KR20060017791A (ko) 2003-06-12 2006-02-27 노보 노르디스크 에이/에스 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7615557B2 (en) 2003-10-01 2009-11-10 Xention Limited Tetrahydro-naphthalene and urea derivatives
US20080009478A1 (en) 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
EP1682486A1 (en) 2003-10-31 2006-07-26 Lica Pharmaceuticals A/S Quaternary amino-functional chalcones
CA2543249C (en) 2003-11-05 2012-08-07 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
WO2005047249A1 (en) 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
WO2005055929A2 (en) 2003-12-02 2005-06-23 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
EP1555264A1 (en) 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
JP2007519735A (ja) 2004-01-30 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用であるｎ−ベンジル−３，４−ジヒドロキシピリジン−２−カルボキサミド及びｎ−ベンジル−２，３−ジヒドロキシピリジン−４−カルボキサミド化合物
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
AU2005220911A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
JP2007527912A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
CN1930161A (zh) 2004-03-09 2007-03-14 P·安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
WO2005086951A2 (en) 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
DE102004015226B3 (de) 2004-03-24 2005-08-25 Siemens Ag Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung
US7297817B2 (en) 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
US20080146585A1 (en) 2004-04-20 2008-06-19 Ab Science Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
US20070293698A1 (en) 2004-04-22 2007-12-20 Allos Therapeutics, Inc. Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same
US20070225293A1 (en) 2004-04-23 2007-09-27 Ab Science Use of C-Kit Inhibitors for Treating Fibrosis
JP2007533731A (ja) 2004-04-23 2007-11-22 アブ サイエンス マラリア原虫関連の疾病を処置するためのｃ−ｋｉｔ阻害剤の使用法
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
CA2566104A1 (en) 2004-05-18 2005-12-01 Ab Science Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1817288A4 (en) 2004-10-28 2009-08-26 Medicure Int Inc DUAL ANTIPLÄTTCHEN / ANTIKOAGULANS PYRIDOXINANALOGE
US20080287399A1 (en) 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
JP5159604B2 (ja) 2005-03-19 2013-03-06 アモーレパシフィック コーポレイション バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd A PYRIDINE DERIVATIVE ANTIPILIC AGENT
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
JP2006306926A (ja) 2005-04-26 2006-11-09 Fuji Photo Film Co Ltd 液晶組成物及び液晶素子
SI3045206T1 (en) 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
US8017635B2 (en) 2005-06-02 2011-09-13 Fmc Corporation Phenylalkyl substituted heteroaryl derivatives
DE102005025989A1 (de) 2005-06-07 2007-01-11 Bayer Cropscience Ag Carboxamide
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
MX2007016492A (es) 2005-06-20 2008-03-07 Astrazeneca Ab Proceso para la preparacion de sales de acido sulfonico de oxabispidinas.
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CN100562514C (zh) * 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
ES2442865T3 (es) 2005-09-16 2014-02-14 Janssen Pharmaceutica N.V. Procedimiento para la preparación de derivados de venzo[E][1,2,4]triazepina-2-ona
WO2007047204A1 (en) 2005-10-11 2007-04-26 University Of Pittsburgh Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins
MX2008005137A (es) 2005-10-27 2008-09-29 Shionogi & Co Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa.
EP1948614A2 (en) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
EP1976851A2 (en) 2006-01-17 2008-10-08 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
JP2009526863A (ja) 2006-02-15 2009-07-23 アラーガン、インコーポレイテッド スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アンタゴニスト生物学的活性を有するアリールまたはヘテロアリール基を持つインドール−３−カルボン酸アミド、エステル、チオアミドおよびチオールエステル化合物
WO2007109783A2 (en) 2006-03-23 2007-09-27 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
EP2418210A1 (en) 2006-04-13 2012-02-15 Vertex Pharmceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP4963863B2 (ja) 2006-04-27 2012-06-27 株式会社Ａｄｅｋａ 新規化合物及び該化合物を含有してなる液晶組成物
ES2498043T3 (es) 2006-06-06 2014-09-24 Cornerstone Therapeutics Inc. Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
EP2044059A1 (en) 2006-06-08 2009-04-08 Speedel Experimenta AG 2,5-disubstituted piperidines
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (zh) 2006-07-26 2008-01-30 中国海洋大学 二氧哌嗪类化合物及其制备方法和用途
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
EP3388417A1 (en) 2006-09-03 2018-10-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
KR20090068345A (ko) 2006-10-23 2009-06-26 머크 앤드 캄파니 인코포레이티드 글루코코르티코이드 수용체 리간드로서의 2-[1-페닐-5-하이드록시-4알파-메틸-헥사하이드로사이클로펜타[ｆ]인다졸-5-일]에틸 페닐 유도체
FR2909379B1 (fr) 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN101558038B (zh) 2006-11-30 2013-05-01 国立大学法人东京工业大学 姜黄素衍生物
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
AU2008206495A1 (en) 2007-01-11 2008-07-24 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having Sphingosine-1-Phosphate (S1P) receptor antagonist biological activity
US8557853B2 (en) 2007-02-09 2013-10-15 Allergan, Inc. Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
WO2008121066A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors
EP2149545B1 (en) 2007-05-22 2016-10-05 Sumitomo Chemical Company, Limited Method for producing benzaldehyde compound
WO2008145616A1 (en) 2007-05-25 2008-12-04 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
KR101158191B1 (ko) 2007-07-17 2012-06-19 에프. 호프만-라 로슈 아게 11ｂ-하이드록시스테로이드 탈수소효소의 억제제
PE20090506A1 (es) 2007-07-26 2009-05-28 Novartis Ag DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
KR20100076022A (ko) 2007-10-17 2010-07-05 노파르티스 아게 Ａｌｋ 억제제로서 유용한 이미다조 [１,２-ａ] 피리딘 유도체
JP2009108152A (ja) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd 重合性化合物および光学フィルム
CN101889010B (zh) 2007-12-04 2012-12-05 弗·哈夫曼-拉罗切有限公司 异*唑-吡啶衍生物
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009149754A (ja) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd 重合性化合物および該重合性化合物を重合してなる光学フィルム
JP2009203230A (ja) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物
US8673970B2 (en) 2008-02-21 2014-03-18 Sequoia Pharmaceuticals, Inc. HIV protease inhibitor and cytochrome p450 inhibitor combinations
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2272817A4 (en) 2008-04-11 2011-12-14 Inst Med Molecular Design Inc INHIBITOR OF PAI-1
MX2010011258A (es) 2008-04-14 2011-06-20 Univ Texas Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
ES2599002T3 (es) * 2008-05-08 2017-01-31 Nova Southeastern University Inhibidores específicos para receptores del factor de crecimiento endotelial vascular
WO2009146555A1 (en) 2008-06-04 2009-12-10 Ambrilia Biopharma Inc. Hiv integrase inhibitors from pyridoxine
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
JP5314330B2 (ja) 2008-06-16 2013-10-16 住友化学株式会社 ２−（アリールオキシメチル）ベンズアルデヒドの製造方法およびその中間体
GB0811451D0 (en) * 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8618300B2 (en) 2008-09-04 2013-12-31 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
JP2010066630A (ja) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd 光学フィルムの製造方法及び光学フィルム
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
AU2009298617A1 (en) 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
SI2356109T1 (sl) 2008-10-10 2017-04-26 Vm Discovery, Inc. Sestavki in postopki za zdravljenje motenj zaradi uživanja alkohola, bolečine in drugih bolezni
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2365809B8 (en) 2008-11-12 2018-10-10 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2010056631A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
US8759520B2 (en) 2008-12-08 2014-06-24 Boehringer Ingelheim International Gmbh Compounds for treating cancer
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
CU24099B1 (es) 2009-01-12 2015-06-30 Pfizer Ltd Derivados de sulfonamida para el tratamiento del dolor
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201033201A (en) * 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
CN104592219B (zh) 2009-03-16 2017-04-12 住友化学株式会社 化合物、光学膜和光学膜的制造方法
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
PL3222277T3 (pl) 2009-03-31 2020-08-24 Ligand Pharmaceuticals Inc. Bifenylosulfonamid będący antagonistą receptora endoteliny i angiotensyny ii do leczenia stwardnienia kłębuszków nerkowych i nefropatii wywołanej iga
EP2427190B1 (en) 2009-05-08 2013-09-18 Tetraphase Pharmaceuticals, Inc. 8-aza tetracycline compounds
JP2011006360A (ja) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
WO2011024869A1 (ja) 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2474540A4 (en) 2009-08-31 2013-03-13 Nippon Chemiphar Co GPR119 AGONIST
WO2011032169A2 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
FI2498756T4 (fi) 2009-11-09 2023-03-22 Neratinibimaleaatin tablettiformulaatiot
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
EP2528898A2 (en) 2010-01-25 2012-12-05 Kareus Therapeutics SA NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD)
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
JP5375644B2 (ja) 2010-02-10 2013-12-25 住友化学株式会社 組成物及び光学フィルム
EP2549873A1 (en) 2010-03-25 2013-01-30 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
KR101698153B1 (ko) 2010-04-26 2017-01-23 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
JP5703594B2 (ja) 2010-05-26 2015-04-22 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
EP3318561B1 (en) 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2593107A1 (en) 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN104478882A (zh) 2010-09-14 2015-04-01 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
CN102116772B (zh) 2010-09-28 2013-08-28 上海大学 二氢查尔酮化合物的筛选方法
KR20130132816A (ko) 2010-10-21 2013-12-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 1-(헤테로시클릭 카르보닐) 피페리딘
PL2630138T3 (pl) 2010-10-21 2015-10-30 Bayer Ip Gmbh 1-(heterocyklo karbonylo)-2-podstawione pirolidyny i ich zastosowanie jako środki grzybobójcze
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
JP5871957B2 (ja) 2011-02-04 2016-03-01 ザ スクリプス リサーチ インスティテュート アルファ−ケト複素環ならびに作製法および使用法
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CA2832650C (en) 2011-04-11 2019-05-07 Pharma Eight Co. Ltd. Pyrazole derivative
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
ES2796774T3 (es) 2011-07-01 2020-11-30 Merck Patent Gmbh Dihidropirazoles, composiciones farmacéuticas de los mismos y su uso para el tratamiento de trastornos de fertilidad
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
LT2736887T (lt) 2011-07-29 2018-02-12 Karyopharm Therapeutics, Inc. Hidrazidą turintys branduolių transporto moduliatoriai ir jų panaudojimas
MX2014001933A (es) 2011-09-15 2014-03-27 Demerx Inc Ansolvatos de sal de noribogaina.
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
PL3738434T3 (pl) 2011-12-28 2024-03-04 Global Blood Therapeutics, Inc. Związki pośrednie do otrzymywania podstawionych związków benzaldehydowych i sposoby ich zastosowania do zwiększania natlenienia tkanek
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
BR112014017021A8 (pt) 2012-01-10 2017-07-04 Nimbus Iris Inc inibidores de irak e usos dos mesmos
CN104603262A (zh) 2012-06-14 2015-05-06 詹森生物科技公司 使人胚胎干细胞分化为胰腺内分泌细胞
WO2013192517A2 (en) 2012-06-21 2013-12-27 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
JP2014005380A (ja) 2012-06-25 2014-01-16 Dic Corp 液晶組成物
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2878040A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
ES2904321T3 (es) 2012-07-27 2022-04-04 Sato Pharma Procedimiento para preparar compuestos de difluorometileno
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
ES2691643T3 (es) 2012-08-24 2018-11-28 Board Of Regents, The University Of Texas System Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades
EP2888253A4 (en) 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
TW201416348A (zh) 2012-08-29 2014-05-01 Gruenenthal Chemie 以氟甲基取代之吡咯甲醯胺
AU2013320972B2 (en) 2012-09-27 2018-08-30 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
US9560850B2 (en) 2012-12-27 2017-02-07 Sumitomo Chemical Company, Limited Tetrazolinone compound and use thereof
US9073946B2 (en) 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CA2902874C (en) 2013-03-15 2021-04-20 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-benzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
EA201591426A1 (ru) 2013-03-15 2016-02-29 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) * 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970315B1 (en) 2013-03-15 2021-09-15 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150256A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150276A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20140127587A (ko) 2013-04-25 2014-11-04 (주)프론트바이오 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
WO2014177464A2 (en) 2013-04-30 2014-11-06 Heinrich-Heine-Universität Düsseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
WO2014194201A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
WO2014194242A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
WO2015058832A1 (en) 2013-10-21 2015-04-30 Merck Patent Gmbh Method of preparing a birefringent polymer film
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN103936659B (zh) 2013-12-12 2016-06-22 石家庄诚志永华显示材料有限公司 含有碳桥联咔唑结构单元的化合物及其制备方法与应用
CN103936658B (zh) 2013-12-12 2016-01-13 石家庄诚志永华显示材料有限公司 含有咔唑结构单元的化合物及其制备方法与应用
KR20150070027A (ko) 2013-12-16 2015-06-24 메르크 파텐트 게엠베하 액정 매질
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
SG11201510135XA (en) 2014-02-07 2016-01-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
DK3110420T3 (da) 2014-02-25 2019-05-13 Board Of Regents Univ Of Texas System Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme
CN106414439B (zh) 2014-03-06 2017-12-08 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
US20150258105A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence
US20150258106A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse
US20150258104A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Use of noribogaine for the treatment of pain
TWI648282B (zh) 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
ES2750791T3 (es) 2014-06-17 2020-03-27 Chiesi Farm Spa Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
DE102015008172A1 (de) 2014-07-28 2016-01-28 Merck Patent Gmbh Flüssigkristalline Medien mit homöotroper Ausrichtung
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
KR102474637B1 (ko) 2014-09-30 2022-12-05 트랜지션즈 옵티칼 인코포레이티드 자외선 광 흡수제
PE20170907A1 (es) 2014-10-07 2017-07-12 Sage Therapeutics Inc Compuestos neuroactivos y metodos de uso de los mismos
WO2016077541A1 (en) 2014-11-12 2016-05-19 The Trustees Of The University Of Pennsylvania Novel anti-infective compounds and methods using same
EP3915639B1 (en) 2014-11-26 2023-06-07 DemeRx, Inc. Methods and compostions for potentiating the action of opioid analgesics using iboga alkaloids
EP3258925B1 (en) 2015-02-19 2023-03-29 Purdue Pharma LP Methods and compositions for decreasing gastric emptying
US10647679B2 (en) 2015-03-15 2020-05-12 Emory University N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
WO2016153951A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc 5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN104876912B (zh) 2015-04-08 2017-07-21 苏州云轩医药科技有限公司 Wnt信号通路抑制剂及其应用
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017039318A1 (en) 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI747889B (zh) 2016-03-16 2021-12-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll抑制劑及使用方法
WO2017184531A1 (en) 2016-04-18 2017-10-26 Demerx, Inc. Treatment of movement-related disorders using noribogaine
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
US20190330167A1 (en) 2016-06-21 2019-10-31 The Walter And Eliza Hall Institute Of Medical Research Activators of hiv latency
WO2017223514A1 (en) 2016-06-24 2017-12-28 Saint Louis University Lxr inverse agonists for treatment of cancer
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CN113316568A (zh) 2018-11-19 2021-08-27 全球血液疗法股份有限公司 能够调节血红蛋白的2-甲酰基-3-羟基苯基氧基甲基化合物

Also Published As

Publication number Publication date
ZA201703791B (en) 2022-08-31
AU2018260808B2 (en) 2020-03-26
JP2016516696A (ja) 2016-06-09
US20190010121A1 (en) 2019-01-10
MY191087A (en) 2022-05-30
EP2970196A1 (en) 2016-01-20
EA034922B1 (ru) 2020-04-07
AP2015008721A0 (en) 2015-09-30
TWI695830B (zh) 2020-06-11
JP2019011373A (ja) 2019-01-24
EP2970196A4 (en) 2016-08-17
BR112015021985B1 (pt) 2022-12-13
IL241060B (en) 2021-09-30
EP2970196B1 (en) 2020-11-25
IL241060A0 (en) 2015-11-30
JP6690861B2 (ja) 2020-04-28
JP2020105228A (ja) 2020-07-09
BR112015021985A2 (pt) 2017-07-18
AU2018260808A1 (en) 2018-11-22
SG11201507320QA (en) 2015-10-29
CL2015002501A1 (es) 2016-04-01
KR20150129725A (ko) 2015-11-20
UY35426A (es) 2014-10-31
KR102280614B1 (ko) 2021-07-21
US20160083343A1 (en) 2016-03-24
EA201591432A1 (ru) 2015-12-30
CA2903220A1 (en) 2014-09-25
SA515361026B1 (ar) 2019-04-07
TW201518274A (zh) 2015-05-16
CN105073728A (zh) 2015-11-18
AU2014237340C1 (en) 2018-11-08
CA2903220C (en) 2023-01-24
SG10201802911RA (en) 2018-05-30
CN112500338A (zh) 2021-03-16
US20190202782A1 (en) 2019-07-04
AU2014237340B2 (en) 2018-08-09
AU2020203882A1 (en) 2020-07-02
US11053195B2 (en) 2021-07-06
AU2014237340A1 (en) 2015-09-17
WO2014150268A1 (en) 2014-09-25
ES2852054T3 (es) 2021-09-10
PE20161035A1 (es) 2016-11-13
JP6426694B2 (ja) 2018-11-21
SA517382253B1 (ar) 2021-11-20

Similar Documents

Publication Publication Date Title
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
AU2018260808A1 (en) Compounds and uses thereof for the modulation of hemoglobin
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
EA202092627A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2020005645A (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
NZ748345A (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EA201590987A1 (ru) Соединения и способы их применения
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
SG10201806867VA (en) Dll3 modulators and methods of use
EA201590997A1 (ru) Соединения и способы их применения
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2017009608A (es) Compuestos anticancerigenos.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.